

## CURRICULUM VITAE

### PERSONAL

Name: **Robert Lawrence Tobin, M.D.**

Title: Medical Director, Department of Radiation Oncology  
Wyoming Medical Center

Born: Casper, Wyoming

Married: Mary Elizabeth Brunken

June 21, 1985

Address:

Wyoming Medical Center  
Dept. Radiation Oncology  
1233 East 2nd Street  
Casper, Wyoming 82601

Phone:

(307) 577-7920

### EDUCATION

Natrona County High School, Casper, Wyoming

Sept. 1975 - May 1979

Creighton University, Omaha, Nebraska

Aug. 1979 - May 1982

Creighton University School of Medicine, Omaha, Nebraska

Aug. 1982 - May 1986

### CERTIFICATION / LICENSURE

Diplomat, National Board of Medical Examiners

July 1987

Medical License - State of Wyoming, Active #4463A

June 1990 to present

**Board Certified - American College of Radiology - Radiation Oncology**

June 1992

*Burch*

### POSTGRADUATE TRAINING

Internal Medicine Internship, Creighton University Affiliate Hospitals

July 1986 - July 1987

Radiation Oncology Residency, Thomas Jefferson University Hospital

July 1987 - June 1990

Radiation Oncology Clinical Fellowship (GI/IORT), Thomas Jefferson  
University Hospital

July 1990 - June 1991

## ADDITIONAL TRAINING

<u>Pediatric Radiation Oncology</u> Elective, St. Jude Children's Research Hospital	Oct. 1988 - Nov. 1988
<u>Hyperthermia</u> Elective, Thomas Jefferson University	Oct. 1989
<u>Cross - Sectional Imaging</u> Elective, Thomas Jefferson University	Sept. 1989
<u>Medical Oncology</u> Elective	July 1990 - Aug. 1990
<u>GI/Intraoperative Radiation Fellowship</u>	Sept. 1990 - April 1991
<u>Radiobiology/Research</u> Elective	May 1991 - June 1991

### *Clinical training and experience in the use of the following:*

<u>Intraoperative Radiation Therapy</u>	(pancreas, rectum sarcomas)
<u>Brachytherapy</u>	(prostate, oral tongue, nasopharynx, breast, endobronchial, Gyn)
<u>Papillion Contact Therapy</u>	(rectum)
<u>Hyperthermia</u>	(head and neck, chest wall)

## AWARDS AND HONORS

Medical Explorer's National Honor Scholarship	1980
President's Certificate of Appreciation for University Service	1981
Member, Creighton University Public Honors and Events Committee	1983
Chief Resident, TJU Department of Radiation Oncology	1990 - 1991
American Cancer Society Clinical Oncology Fellowship (paid stipend for clinical research)	1990 - 1991

## PROFESSIONAL SOCIETY MEMBERSHIPS

### *National Societies*

American Cancer Society National Professional Assembly Delegate	1996 - 1997
American Cancer Society Wyoming chapter President	1997
American Medical Association	

American Society for Therapeutic Radiology and Oncology (ASTRO)  
American College of Radiology

*State*

American Cancer Society Wyoming state board member 1992 - present  
State Board of Directors - Wyoming Breast and Cervical Cancer Coalition 1994 - 1995  
Wyoming State Medical Society

*Local (Medical Staff appointments and positions)*

Board Member - Central Wyoming Cancer Treatment Center and Hospice 1992 - 1993  
Professional Member of WMC Radiation Safety Committee 1992 - present  
Professional Member of WMC Education Committee 1992 - present  
Chairman of WMC Medical Ethics Committee 1994 - 1995  
President - Blue Envelope Cancer Division 1995 - present  
Secretary/Treasurer of the Medical Staff at WMC 1995 - 1997  
Chief of Medical Staff 1997 - 1999

**PUBLICATIONS / PRESENTATIONS**

**Tobin, R. L.;** Fontanesi, J.; Kun, L.E.; et al. Wilms' tumor: Reduced - dose radiotherapy in advanced-stage Wilms' tumor with favorable histology. *Int. J. Radiat. Oncol. Biol. Phys.* 19:867-871; 1990. (Presented at the 1989 National ASTRO convention in San Francisco, CA.)

**Tobin, R. L.;** Mohuiddin, M. Preoperative radiation for cancer of the rectum with extra-rectal fixation. *Int. J. Radiat. Oncol. Biol. Phys.* 21:1-6; 1991.  
(Presented at the 1990 National ASTRO convention in Miami Beach, FL)

“Preoperative Radiation for Unfavorable Carcinoma of the Rectum - TJU experience”  
presented to the Thomas Jefferson University Colorectal Conference Nov. 1990

“Intraoperative radiotherapy for pancreatic carcinoma - TJU experience” presented at  
Thomas Jefferson University GI Oncology Conference Feb. 1991

**PROFESSIONAL PRESENTATIONS**

“Treatment Options for Rectal Carcinoma” presented at the CME conference at the Wyoming  
Medical Center in Casper, Wyoming April 1991

“Oncology Update - Tumor Markers, Breast Cancer, Prostate Cancer and Ovarian Cancer”  
presented at CME conferences in Casper, Douglas, Lander, Riverton, Rawlins, Buffalo, and  
Gillette, Wyoming Aug. - Oct. 1991

- “Breast Preservation Oncology Update” presented at the CME conference at the Wyoming Medical Center in Casper, Wyoming Nov. 1991
- “Oncology Update - Prostate Cancer” presented at the State Society of Radiology Technologists and Therapists Convention in Cody, Wyoming Oct. 1992
- “Oncology Update - Breast Cancer” presented at the State Society of Radiology Technologists and Therapists Convention in Casper, Wyoming May 1993
- “Breast Cancer Update 1993" presented to Lander Valley Medical Center Cancer Support Group and Nurses Sept. 1993
- “Cancer Screening Update” presented to Blue Envelope Annual Banquet March 1994
- “Management of Invasive and Non-Invasive Breast Carcinoma” presented to a physician CME update in Riverton, Wyoming March 1994
- “Breast Carcinoma Update - Where do we go from here?” presented to the Casper meeting of the Wyoming Breast and Cervical Cancer Coalition Committee April 1994
- Frontiers in Medicine - Moderator: Colorectal carcinoma session (Cartwright, Johnson, Marks, Mo) Jan. 1993
- Frontiers in Medicine - “Application of Radiation Therapy for Palliation of Cancer Pain” Feb. 1996



Community Development  
 1233 East 2nd Street  
 Casper, WY  
 82601

## FACSIMILE COVER PAGE

TO	<i>Nuclear Regulatory Commission</i>		
FAX	<i>917-860-8263</i>	PHONE	
FROM	<i>CHRIS LORENZEN</i>	PHONE	<i>307-577-2576</i>
TOTAL PAGES	<i>3</i>		
DATE	<i>2-10-04</i>	TIME	
SUBJECT	<i>RSO CHANGE</i>		
COMMENTS	<i>PAPER COPY TO FOLLOW IN MAIL.</i>		

If You Do Not Receive All Pages or If Documents Are Unreadable, Contact the Community Development department at or (Fax)

ntal

## Wyoming Medical Center

1233 E. Second St.  
Casper, WY 82601  
307 577 7201

February 10, 2004

U.S. Nuclear Regulatory Commission  
Region IV  
Radioactive Materials Licensing  
Texas Health Resources Tower  
611 Ryan Plaza, Suite 400  
Arlington, TX 76011-8064

Dear Sir or Madam,

**Subject: Amendment to Radioactive Material License No. 49-00152-02 to change  
Radiation Safety Officer**

This is a request to remove Marcel Szal as Radiation Safety Officer for Wyoming Medical Center, License number 49-00152-02. Mr. Szal resigned as Wyoming Medical Center's Medical Physicist and RSO as of February 11, 2004. To replace Mr. Szal as RSO, we would like to add Robert Lawrence Tobin, M.D. to our Radioactive Material License as RSO.

Robert L. Tobin, M.D. is an authorized user under 10CFR35.300, 10CFR35.400 and Phosphorus-32.

Please contact Chris Lorenzen at 307-577-2576 if you have any questions or need additional information.

Sincerely,



Chris Lorenzen  
*Director of Oncology Services*



Pam Fulks  
*Chief Executive Officer*

# After American Board of Radiology

Organized through the cooperation of the American College of Radiology, the American Roentgen Ray Society, the American Radiology Society, the Radiological Society of North America, the Section on Radiology of the American Medical Association, the American Society for Therapeutic Radiology and Oncology, the Association of University Radiologists, and American Association of Physicians in Residence Study, called that

Robert L. Tobin, M.D.


Has finished an accepted course of graduate study and clinical work, has met certain standards and qualifications and has passed the examinations conducted under the authority of

The American Board of Radiology

On this fourth day of June, 1992

Chief, Membership & Administration of the Board

Woburn, Ontario



SPONSOR: 98CA02 WMC

CANCER CONFERENCE 01/07/1998  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 98CA01 WMC

CANCER CONFERENCE 12/24/1997  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 97CA49 WMC

CANCER CONFERENCE 12/17/1997  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 97CA48 WMC/BREAST

CANCER CONFERENCE 12/03/1997  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 97CA46 WMC

CANCER CONFERENCE 11/26/1997  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 97CA45 WMC

ACUTE AND CHRONIC PAIN:PATIENTS SPECIFIC MODALITY 11/18/1997  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 97CME41 WMC

CANCER CONFERENCE 11/12/1997  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 97CA43 WMC

CANCER CONFERENCE 11/05/1997  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 97CA42 WMC

ONCOLOGY ANNUAL MEETING/THERAPEUTIC RADIOLOGY 10/19/1997  
HOURS: 30.00 CATEGORY: I  
SPONSOR: 97OT85 AMERICAN COLLEGE OF RADIOLOGY

CANCER CONFERENCE 10/15/1997  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 97CA39 WMC

NEW TREATMENTS FOR BPH 10/14/1997  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 97CME35 WMC

CANCER CONFERENCE 10/08/1997  
HOURS: 1.00 CATEGORY: I

SPONSOR: 01FRONTIER WMC

CANCER CONFERENCE 01/31/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA03 WMC (BREAST)

RADIATION ONCOLOGY CONFERENCE 01/26/2001  
HOURS: 16.00 CATEGORY: I  
SPONSOR: 01MD85 INDIANA UNIVERSITY SCHOOL OF MEDICINE

CANCER CONFERENCE 01/10/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA01 WMC

CANCER CONFERENCE 11/15/2000  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 00CA35 WMC

CANCER CONFERENCE 11/15/2000  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 00CA36 WMC

CANCER CONFERENCE 11/01/2000  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 00CA34 WMC

CANCER CONFERENCE 10/25/2000  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 00CA33 WMC

WHAT INTERVENTIONAL RADIOLOGY CAN DO FOR YOU AN 10/24/2000  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 00CME56 WMC

CANCER CONFERENCE 10/18/2000  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 00CA32 WMC

CANCER CONFERENCE 10/11/2000  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 00CA31 WMC

COMMUNITY ACQUIRED PNEUMONIA, WHAT'S NEW 10/10/2000  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 00CME53 WMC

PHYSICIAN PRACTICES COMMUNICATIONS AND DOCUMENTATI 09/29/2000  
HOURS: 1.50 CATEGORY: I

SPONSOR: 01CA26 WMC

CANCER CONFERENCE 10/03/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA25 WMC (BREAST)

CANCER CONFERENCE 09/19/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA24 WMC

STEREOTACTIC RADIOSURGERY 09/18/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CME38 WMC

CANCER CONFERENCE 09/12/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA23 WMC (bBREAST)

CANCER CONFERENCE 08/29/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA22 WMC

CANCER CONFERENCE 08/22/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA21 WMC

CANCER CONFERENCE 08/15/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA20 WMC

CANCER CONFERENCE 08/08/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA19 WMC (BREAST)

CANER CONFERENCE 08/01/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA18 WMC

CANCER CONFERENCE 07/25/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA17 WMC (BREAST)

CANCER CONFERENCE 07/11/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA16 WMC (BREAST)

CANCER CONFERENCE 06/27/2001  
HOURS: 1.00 CATEGORY: I

CENTER

CANCER CONFERENCE 01/09/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CA01 WMC

HYPERBARIC OXYGEN THERAPY 01/08/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CME01 WMC

CANCER CONFERENCE 12/12/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA34 WMC

CANCER CONFERENC 12/05/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA33 WMC

CANCER CONFERENCE 11/28/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA32 WMC

CANCER CONFERENCE 11/21/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA31 WMC (BREAST)

CANCER CONFERENCE 11/14/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA30 WMC (BREAST)

GUIDELINES FOR THE DIAGNOSIS AND MGMT OF MELANOMA 10/30/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CME48 WMC

CANCER CONFERENCE 10/24/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA28 WMC

SPASTICITY TREATMENT OPTIONS 10/23/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CME46 WMC

CANCER CONFERENCE 10/17/2001  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 01CA27 WMC

CANCER CONFERENCE 10/10/2001  
HOURS: 1.00 CATEGORY: I

CANCER CONFERENCE 05/08/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CA14 WMC

NEWER ANTIEPILEPTIC DRUGS IN THE MGMT OF PSYCHIATR 05/07/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CME17 WMC

CANCER CONFERENCE 04/24/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CA13 WMC (BREAST)

CANCER CONFERENCE 04/10/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CA10 WMC (BREAST)

CANCER CONFERENCE 04/03/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CA11 WMC

CANCER CONFERENCE 03/20/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CA09 WMC (BREAST)

CANCER CONFERENCE 02/27/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CA07 WMC (BREAST)

CANCER CONFERENCE 02/20/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CA06 WMC (BREAST)

CANCER CONFERENCE 02/13/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CA05 WMC (BREAST)

CANCER CONFERENCE 02/06/2002  
HOURS: 1.00 CATEGORY: I  
SPONSOR: 02CA04 WMC

2ND ANNUAL OCOLOGY UPDATE ADVANCES AND CONTROVERSI 01/19/2002  
HOURS: 17.00 CATEGORY: I  
SPONSOR: 02MD27 UNIVERSITY OF TEXAS

2ND ANNUAL ONCOLOGY UPDATE: ADVANCES & CONTROVERSI 01/19/2002  
HOURS: 18.50 CATEGORY: I  
SPONSOR: 02MD66 UNIVERSITY OF TEXAS M.D. ANDERSON CANCER



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
REGION IV  
611 RYAN PLAZA DRIVE, SUITE 400  
ARLINGTON, TEXAS 76011-4005

March 23, 2005

Wyoming Medical Center  
ATTN: Robert L. Tobin, M.D.  
Radiation Safety Officer  
1233 East Second Street  
Casper, Wyoming 82601

SUBJECT: LICENSE AMENDMENT

Please find enclosed Amendment No. 68 to License No. 49-00152-02, **adding Dr. David Williams as an authorized user for 10 CFR 35.100, 35.200, 35.300, and 31.11 uses. Please note that although this license shows that it expired on December 31, 2004, it will remain in effect until the Agency completes its renewal process.** An environmental assessment for this action is not required, since this action is categorically excluded under Title 10 of the Code of Federal Regulations, Part 51.22(c)(14)(iv). You should review this license carefully and be sure that you understand all conditions. If you have any questions, you may contact me at 817-860-8189.

NRC expects licensees to conduct their programs with meticulous attention to detail and a high standard of compliance. Because of the serious consequences to employees and the public that can result from failure to comply with NRC requirements, you must conduct your radiation safety program according to the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate by NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers: Inspection and Investigations," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC in writing of any change in mailing address.
3. By 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:
  - a. When you decide to terminate all activities involving materials authorized under the license whether at the entire site or any separate building or outdoor area; or
  - b. If you decide not to acquire or possess and use authorized material; or
  - c. When no principal activities under the license have been conducted for a period of 24 months.

4. In accordance with 10 CFR 35.14, notify the NRC no later than 30 days after:
  - a. The date that the licensee permits an individual to work as an authorized user, an authorized nuclear pharmacist or an authorized medical physicist under 10 CFR 35.13(b)(1) through (b)(4);
  - b. An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, or an authorized medical physicist permanently discontinues duties under the license or has a name change;
  - c. The licensee's mailing address changes;
  - d. The licensee's name changes, but the name change does not constitute a transfer of control of the license as described in 10 CFR 30.34(b); or
  - e. The licensee has added to or changed the areas of use identified in the application or on the license where byproduct material is used in accordance with either 35.100 or 35.200.
5. Request and obtain a license amendment before you:
  - a. Change Radiation Safety Officers;
  - b. Order byproduct material in excess of the amount, radionuclide or form authorized on the license;
  - c. Add or change the areas or address(es) of use identified in the license application or on the license, except for areas of use where byproduct material is used only in accordance with either 10 CFR 35.100 or 35.200; or
  - d. Change the name or ownership of your organization.
6. Submit a complete renewal application or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.

In addition, please note that NRC Form 313 requires the applicant, by signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant. Since the NRC also accepts a letter requesting amendment or renewal of an NRC license, the signatory for such a request should also be the licensee or certifying official rather than a consultant.

NRC will periodically inspect your radiation safety program. Failure to conduct your program according to NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC may result in enforcement action against you. This could include issuance of a notice of violation; imposition of a civil penalty; or an order suspending, modifying, or revoking your license as specified in the "General Statement of Policy and Procedure for NRC Enforcement Actions" (Enforcement Policy), NUREG 1600.

The NRC no longer publishes the NRC Rules and Regulations loose leaf supplements due to budget constraints. However, an electronic version of the NRC's regulations is available on the NRC Web site at [www.nrc.gov](http://www.nrc.gov). To view these regulations, highlight "Electronic Reading Room" and choose "Regulations" on the drop down menu. An electronic version of the NUREG-1556 Series publications is also available on the NRC Web site. To view these guidance documents, highlight "Electronic Reading Room"; choose "All Document Types" on the drop down menu; scroll down to "NUREG-Series Publications"; and select "Publications Prepared by the NRC Staff". Then, choose "NUREG-1556" from the table and select the appropriate volume(s) for your license type.

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at <http://www.nrc.gov/reading-rm/adams.html>.

Please note that on October 25, 2004, the NRC suspended public access to ADAMS, and initiated an additional security review of publicly available documents to ensure that potentially sensitive information is removed from the ADAMS database accessible through the NRC's web site. Interested members of the public may obtain copies of the referenced documents for review and/or copying by contacting the Public Document Room pending resumption of public access to ADAMS. The NRC Public Document Room is located at NRC Headquarters in Rockville, MD, and can be contacted at 800-397-4209 or 301-415-4737 or [pdr@nrc.gov](mailto:pdr@nrc.gov).

Thank you for your cooperation.

Sincerely,

**/RA/**

Roberto J. Torres, Senior Health Physicist  
Nuclear Materials Licensing Branch

Docket: 030-03495  
License: 49-00152-02  
Control: 470351

Enclosure: As stated

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated December 28, 2004
1. Wyoming Medical Center	3. License number 49-00152-02 is amended in its entirety to read as follows:
2. 1233 East Second Street Casper, Wyoming 82601	4. Expiration date December 31, 2004
	5. Docket No. 030-03495

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 (Except gases)	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. 1 curie
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. As needed
E. Any byproduct material identified in 10 CFR 35.500	E. Sealed sources for diagnostic devices identified in 10 CFR 35.500	E. 1.5 curies per source
F. Any byproduct material identified in 10 CFR 31.11	F. Prepackaged kits	F. As needed
G. Yttrium-90	G. Unsealed liquid radiopharmaceutical sources (IDEC Pharmaceuticals Zevalin)	G. Not to exceed two sources, 110 millicuries total activity
H. Phosphorus-32	H. Sealed sources (Guidant Corp. VI, GDT P-32 Series)	H. 600 millicuries per source assembly, 2 source assemblies total

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
49-00152-02

Docket or Reference Number  
030-03495

Amendment No. 68

9. Authorized use:
- A. Medical use described in 10 CFR 35.100.
  - B. Medical use described in 10 CFR 35.200.
  - C. Medical use described in 10 CFR 35.300.
  - D. Medical use described in 10 CFR 35.400 and Cesium-137 for calibration of licensee's survey meters and personnel dosimeters.
  - E. Medical use described in 10 CFR 35.500.
  - F. In vitro studies.
  - G. To be used for dose calibrator checks and calibrations and quality assurance testing.
  - H. Notwithstanding the requirements of 10 CFR 35.400, for use in Guidant Corporation VI Model Galileo Intravascular Brachytherapy High Dose Rate Afterloader devices for intravascular brachytherapy.

**CONDITIONS**

- 10. Licensed material may be used or stored only at the licensee's facility located at 1233 East Second Street, Casper, Wyoming.
- 11. The Radiation Safety Officer for this license is Robert Lawrence Tobin, M.D.
- 12. Licensed Material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical and non-medical uses:

Authorized Users

Material and Use

Paul Peters, M.D.	35.100, 35.200, 35.300, 35.500, and 31.11
Michael E. Walker, M.D.	35.100, 35.200, 35.300, 35.500, and 31.11
Stephen R. Horn, M.D.	35.100, 35.200, 35.300, 35.500, and 31.11
Geoffrey G. Smith, M.D.	35.100, 35.200, 35.300, and 31.11
Robert Lawrence Tobin, M.D.	35.300, 35.400 and Phosphorus-32

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
49-00152-02

Docket or Reference Number  
030-03495

Amendment No. 68

Authorized Users

Material and Use

Thomas M. Cunningham III, M.D.	35.100, 35.200, 35.500, and 31.11
Wesley W. Hiser, M.D.	35.200
Daniel F. Sulser, M.D.	35.100, 35.200, 35.300, and 31.11
Steven Richard Bonin, M.D.	35.300, 35.400 and Phosphorus-32
David K. Williams, M.D.	35.100, 35.200, 35.300, and 31.11

C. The following individual is an authorized medical physicist:

Authorized Medical Physicist

Material and Use

Robert C. Gregory, M.S.	Phosphorus-32 for uses in Intravascular Brachytherapy High Dose Rate Afterloader devices for calibrations, spot checks, and training
-------------------------	--

D. Intravascular brachytherapy procedures shall be conducted under the supervision of the authorized user, who will consult with the interventional cardiologist/physician and authorized medical physicist prior to initiating treatment. The procedures shall be conducted in the physical presence of the authorized user or the authorized medical physicist.

13. A. The licensee shall use the material in Subitem 6.G. in accordance with all appropriate radiation safety program elements contained in this license and referenced in Condition No. 15.
- B. The licensee shall use remote handling tools and low-density plastic shielding for vials, syringes, and wastes when handling the material in Subitem 6.G.
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
49-00152-02Docket or Reference Number  
030-03495

Amendment No. 68

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated May 17, 1994
  - B. Letter dated July 2, 1998
  - C. Letter dated October 4, 1999
  - D. Letter dated May 17, 2002
  - E. Letter dated August 9, 2002

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: March 23, 2005By: IRAJack E. Whitten, Chief  
Nuclear Materials Licensing Branch  
Region IV  
Arlington, Texas 76011